{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:28:52Z","timestamp":1780990132427,"version":"3.54.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>A 63-year-old Black woman presented with progressive exertional dyspnea and chronic lower back pain. The course and findings in her case are instructive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case report<\/jats:title><jats:p>Family history was notable for cardiac deaths. An echocardiogram demonstrated ventricular wall thickening with diastolic dysfunction. The patient\u2019s N-terminal pro b-type natriuretic peptide level was 1,691\u2005pg\/ml with a troponin I level of 0.36\u2005ng\/ml. Transthyretin (TTR) sequencing detected a heterozygous V122I variant. The patient\u2019s free <jats:italic>\u03ba<\/jats:italic> light chain level in serum was 664\u2005mg\/L with a ratio of 16.5. Bone marrow analysis showed 20%\u201330% \u03ba-restricted plasma cells with amyloid deposits. A technetium-99m sodium pyrophosphate scan was performed and was negative. Magnetic resonance imaging of the total spine showed ligamentum flavum (LF) thickening at L4\u20135, causing severe spinal stenosis. In both the abdominal fat and the LF, liquid chromatography-coupled tandem mass spectrometry confirmed \u03ba-type immunoglobulin light chain (AL) amyloidosis; the quantitative estimate of amyloid content in the LF was 5%. She was diagnosed with AL amyloidosis with Mayo Stage IIIA cardiac and soft tissue involvement, enrolled in the Aquarius trial (NCT05250973) in Cohort 2, and received daratumumab, cyclophosphamide, bortezomib, and dexamethasone. She achieved a partial hematological response with a cardiac response and is now pain-free and fully functional.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with amyloidosis who have both monoclonal gammopathy and a TTR variant, it is imperative to discern the tissue type of the amyloid to deduce the correct diagnosis. ATTR and AL amyloidosis can both cause spinal stenosis with minimal degenerative changes. The LF tissue must be stained for amyloids and, if present, typing must be performed.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2024.1479676","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:19:45Z","timestamp":1734329985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Avoiding misdiagnosis in amyloidosis\u2014navigating transthyretin genopositivity and monoclonal gammopathy in a patient with advanced heart failure and spinal stenosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Xia","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Toskic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parva","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Fogaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Pilichowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knarik","family":"Arkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jainith","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron I.","family":"Riesenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13681","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","volume":"107","author":"Oubari","year":"2021","journal-title":"Eur J Haematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1182\/blood-2005-10-4148","article-title":"Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins","volume":"107","author":"Comenzo","year":"2006","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"95","author":"Gertz","year":"2020","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1016\/j.jpi.2022.100013","article-title":"Machine learning quantification of amyloid deposits in histological images of ligamentum flavum","volume":"13","author":"Wang","year":"2022","journal-title":"J Pathol Inform"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/s-0039-1688994","article-title":"Neuropathy associated with systemic amyloidosis","volume":"39","author":"Kaku","year":"2019","journal-title":"Semin Neurol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020712-163913","article-title":"AA Amyloidosis: pathogenesis and targeted therapy","volume":"10","author":"Westermark","year":"2015","journal-title":"Annu Rev Pathol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/bjh.16487","article-title":"The prevalence and significance of monoclonal gammopathy of undetermined significance in acute medical admissions","volume":"189","author":"Atkin","year":"2020","journal-title":"Br J Haematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ahj.2009.08.006","article-title":"Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis","volume":"158","author":"Connors","year":"2009","journal-title":"Am Heart J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/mgg3.231","article-title":"The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa","volume":"4","author":"Jacobson","year":"2016","journal-title":"Mol Genet Genomic Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.amjcard.2023.06.022","article-title":"How often does apical sparing of longitudinal strain indicate the presence of cardiac amyloidosis?","volume":"202","author":"Wali","year":"2023","journal-title":"Am J Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcmg.2013.08.015","article-title":"CMR-based differentiation of AL and ATTR cardiac amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"B18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3109\/13506129.2015.1020153","article-title":"Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging","volume":"22","author":"Kristen","year":"2015","journal-title":"Amyloid"},{"key":"B19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12968-018-0478-3","article-title":"Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis","volume":"20","author":"Ridouani","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"B20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jcmg.2020.07.030","article-title":"Novel cardiovascular magnetic resonance model to distinguish immunoglobulin light chain from transthyretin cardiac amyloidosis","volume":"14","author":"Slivnick","year":"2021","journal-title":"Cardiovasc Imaging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"oead092","DOI":"10.1093\/ehjopen\/oead092","article-title":"Prognosis prediction in cardiac amyloidosis by cardiac magnetic resonance imaging: a systematic review with meta-analysis","volume":"3","author":"Boretto","year":"2023","journal-title":"Eur Heart J Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1093\/eurheartj\/ehac363","article-title":"Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment","volume":"43","author":"Martinez-Naharro","year":"2022","journal-title":"Eur Heart J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/13506129.2011.630762","article-title":"Proteomic typing of amyloid deposits in systemic amyloidoses","volume":"18","author":"Lavatelli","year":"2011","journal-title":"Amyloid"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.jacc.2020.04.022","article-title":"Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week","volume":"75","author":"Hanna","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5837\/bjc.2021.015","article-title":"Amyloid heart disease module 1: diagnosis","author":"Krepp","year":"2021","journal-title":"Br J Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2147\/TCRM.S185677","article-title":"Diagnosis and screening of patients with hereditary transthyretin amyloidosis (hATTR): current strategies and guidelines","volume":"16","author":"Benson","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jcmg.2020.08.027","article-title":"Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99\u2005m pyrophosphate: a test in evolution","volume":"14","author":"Poterucha","year":"2021","journal-title":"Cardiovasc Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/13506129.2023.2267162","article-title":"Inappropriate use of technetium-99m pyrophosphate scanning for the evaluation of transthyretin amyloidosis","volume":"31","author":"Yan","year":"2024","journal-title":"Amyloid"},{"key":"B29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/13506129.2018.1449104","article-title":"Once AL amyloidosis: not always AL amyloidosis","volume":"25","author":"Jhaveri","year":"2018","journal-title":"Amyloid"},{"key":"B30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41408-019-0193-9","article-title":"Two types of amyloidosis presenting in a single patient: a case series","volume":"9","author":"Sidiqi","year":"2019","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.wneu.2023.06.037","article-title":"The emerging significance of amyloid deposits in the ligamentum flavum of spinal stenosis patients: a review","volume":"177","author":"Wang","year":"2023","journal-title":"World Neurosurg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2023.2230516","article-title":"Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis","volume":"30","author":"Marchi","year":"2023","journal-title":"Amyloid"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.25259\/SNI_1235_2021","article-title":"Unraveling a rare cause of spinal stenosis: coexistent AL and ATTR amyloidosis involving the ligamentum flavum","volume":"13","author":"Godara","year":"2022","journal-title":"Surg Neurol Int"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.wneu.2022.04.008","article-title":"The relationship between wild-type transthyretin amyloid load and ligamentum flavum thickness in lumbar stenosis patients","volume":"164","author":"Wang","year":"2022","journal-title":"World Neurosurg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3171\/2022.5.SPINE22362","article-title":"Lumbar stenosis due to wild-type transthyretin amyloid\u2013induced thickening of the ligamentum flavum: a separate etiology from degeneration of intervertebral discs?","volume":"1","author":"Wang","year":"2022","journal-title":"J Neurosurg Spine"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1479676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:19:48Z","timestamp":1734329988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2024.1479676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":35,"alternative-id":["10.3389\/fcvm.2024.1479676"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2024.1479676","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1479676"}}